Phase 1 N=43 3BNC117-LS First-in-Human Phase 1 Study
Human Immunodeficiency Virus
Primary: The Number of Participants Who Experience Adverse Events Within 2 Weeks After 3BNC117-LS Infusion in All Study Groups — 0; 0; 1; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=60 Aborption and Metabolism of Lyophilized Black Raspberry Food Products in Men With Prostate Cancer Undergoing Surgery
Stage I Prostate Cancer · Stage IIA Prostate Cancer · Stage IIB Prostate Cancer
Primary: Adverse Events Assessed Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 — 0; 0; 0; 0 Participants
Phase 1 N=16 Psilocybin-assisted CBT for Depression
Major Depressive Disorder
Primary: Treatment Acceptability (Client Satisfaction Questionnaire-8) — 30.8 scores on a scale
Phase 1 N=51 Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers
COVID-19
Primary: Area Under the Concentration-time Curve From Time Zero to Infinity [Extrapolated] (AUC0-inf): ALG-097558 in Part A and Part C, Dabigatran (Total) in Plasma in Part B…
Phase 1 N=82 First-In-Human (FIH) Trial Evaluating the Safety and Tolerability of Single and Multiple Ascending Oral Doses of IRL757 in Healthy Volunteers
Not Determined
Primary: Evaluation of Frequency, Seriousness and Intensity of Adverse Events — 7; 1; 3; 4 Adverse events
Phase 1 N=6 Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)
B-precursor Acute Lymphoblastic Leukemia
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and Treatment-related TEAEs — 5; 1; 1; 0 Participants
Phase 1 N=96 Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of BI 425809 Tablets for 12 Days to Young and Elderly Healthy Male and Female Volunteers and Comparison of Pharmacokinetics of a Single Oral Dose of BI 425809 (Morning Versus Evening)
Healthy
Primary: Percentage of Subjects With Drug Related Adverse Events (AEs) in Part I — 46.7; 50.0; 44.4; 66.7 Percentage of participants
Phase 1 N=7 A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002)
Mature B-cell Neoplasms
Primary: Number of Participants Who Experience Dose Limiting Toxicities (DLTs) Per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version…
Phase 1 N=14 A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1815368 in the Blood
Healthy
Primary: Area Under the Concentration-time Curve of BI 1815368 Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) — 3876.73; 8178.83 nanomoles*hour/Liter (nmol*h/L)
Phase 1 N=31 Dose Escalation Study With Expansion to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of CCT3833
Melanoma · Cancer
Primary: Number and Percentage of Patients With Dose Limiting Toxicities (DLT). — 0; 0; 0; 0 Participants
Phase 1 N=30 A Study of TAK-881 and HyQvia in Healthy Adults
Healthy Volunteers
Primary: Baseline-corrected Area Under the Concentration-time Curve (AUC) From Day 1 to Day 29 (AUC Day 1-29) Based on Serum Total Immunoglobulin G (IgG) Levels — 2993; 3190…
Phase 1 N=88 Is Obstructive Sleep Apnea Important in the Development of Alzheimer's Disease?
OSA · Sleep Apnea · Obstructive Sleep Apnea
Primary: Apnea Hypopnea Index - Crossover — 34.9; 39.6 units on a scale
Phase 1 N=17 A Study in Healthy Women to Test Whether BI 425809 Influences the Amount of a Contraceptive in the Blood
Healthy
Primary: Area Under the Concentration-time Curve of Ethinylestradiol (EE) in Plasma at Steady State Over a Uniform Dosing Interval τ (AUCτ,ss) — 916.63; 942.17…
Phase 1 N=8 A Study on Oral and Intranasal Forms of Oxycodone in Healthy Volunteers Using Pharmacokinetic Modeling
Physiologically Based Pharmacokinetic · Healthy Volunteers
Primary: AUC(0-24h) — 7373.6; 7195.7 ng·min/mL
Phase 1 N=8 Pharmacokinetics of Intravenous and Intranasal Formulations of Naloxone in Healthy Volunteers.
Healthy
Primary: Effects of Naloxone on Heart Rate (HR). — 73.3; 70.6 bpm